PDCD1 and Miyoshi myopathy: Therefore, the combination therapy with DCs plus novel agents including lenalidomide or PD-1 inhibiter may modulate anti-tumor immune deficiency and promote cytotoxicity against MM cells, compared with a DC vaccine alone.